JP2014526562A5 - - Google Patents

Download PDF

Info

Publication number
JP2014526562A5
JP2014526562A5 JP2014532075A JP2014532075A JP2014526562A5 JP 2014526562 A5 JP2014526562 A5 JP 2014526562A5 JP 2014532075 A JP2014532075 A JP 2014532075A JP 2014532075 A JP2014532075 A JP 2014532075A JP 2014526562 A5 JP2014526562 A5 JP 2014526562A5
Authority
JP
Japan
Prior art keywords
therapeutic agent
disorder
superoxide dismutase
agent according
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014532075A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526562A (ja
JP6267638B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/056921 external-priority patent/WO2013048965A1/en
Publication of JP2014526562A publication Critical patent/JP2014526562A/ja
Publication of JP2014526562A5 publication Critical patent/JP2014526562A5/ja
Application granted granted Critical
Publication of JP6267638B2 publication Critical patent/JP6267638B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014532075A 2011-09-26 2012-09-24 疾患の治療方法 Active JP6267638B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161539365P 2011-09-26 2011-09-26
US61/539,365 2011-09-26
PCT/US2012/056921 WO2013048965A1 (en) 2011-09-26 2012-09-24 Methods for treatment of diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017172825A Division JP6382416B2 (ja) 2011-09-26 2017-09-08 疾患の治療方法

Publications (3)

Publication Number Publication Date
JP2014526562A JP2014526562A (ja) 2014-10-06
JP2014526562A5 true JP2014526562A5 (enExample) 2015-11-12
JP6267638B2 JP6267638B2 (ja) 2018-01-24

Family

ID=47911939

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2014532075A Active JP6267638B2 (ja) 2011-09-26 2012-09-24 疾患の治療方法
JP2017172825A Active JP6382416B2 (ja) 2011-09-26 2017-09-08 疾患の治療方法
JP2018145207A Active JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法
JP2020121417A Active JP7562125B2 (ja) 2011-09-26 2020-07-15 疾患の治療方法
JP2022200192A Active JP7697688B2 (ja) 2011-09-26 2022-12-15 疾患の治療方法
JP2025094341A Pending JP2025131753A (ja) 2011-09-26 2025-06-05 疾患の治療方法

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2017172825A Active JP6382416B2 (ja) 2011-09-26 2017-09-08 疾患の治療方法
JP2018145207A Active JP6736618B2 (ja) 2011-09-26 2018-08-01 疾患の治療方法
JP2020121417A Active JP7562125B2 (ja) 2011-09-26 2020-07-15 疾患の治療方法
JP2022200192A Active JP7697688B2 (ja) 2011-09-26 2022-12-15 疾患の治療方法
JP2025094341A Pending JP2025131753A (ja) 2011-09-26 2025-06-05 疾患の治療方法

Country Status (8)

Country Link
US (7) US9149483B2 (enExample)
EP (1) EP2760874A4 (enExample)
JP (6) JP6267638B2 (enExample)
CN (2) CN111467351A (enExample)
AU (5) AU2012316397B2 (enExample)
CA (2) CA3120505C (enExample)
HK (1) HK1199261A1 (enExample)
WO (1) WO2013048965A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2056675T (lt) 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
CA3120505C (en) 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
TWI746449B (zh) * 2015-07-20 2021-11-21 美商Ai治療公司 使用阿吡莫德治療癌症之方法
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
MX393974B (es) * 2016-05-03 2025-03-24 Galera Labs Llc Terapia de combinacion para tratamiento de cancer.
JP7166634B2 (ja) * 2016-09-01 2022-11-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法
JP2020507598A (ja) * 2017-02-15 2020-03-12 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc 局所腸送達のためのペンタアザマクロ環錯体
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
AU2019215032A1 (en) * 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent
CN114502179A (zh) * 2019-10-10 2022-05-13 加莱拉实验室有限责任公司 含锰配合物的水性制剂的制备方法、制剂和治疗方法
CA3167087A1 (en) * 2020-02-13 2021-08-19 Anantha Rajmohan MUTHUSAMY Solid state forms of avasopasem manganese and process for preparation thereof
US20250195624A1 (en) * 2022-02-21 2025-06-19 Isocell S.A.S. Use of superoxide dismutase for the treatment and/or prevention of allergic asthma
WO2025259817A1 (en) * 2024-06-12 2025-12-18 Galera Labs, Llc Methods for reduced tissue damage from radiopharmaceuticals with superoxide-reducing agent

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001212A (en) 1973-10-03 1977-01-04 E. I. Du Pont De Nemours And Company Macrocyclic polyamines
US3930867A (en) 1974-01-07 1976-01-06 E. I. Du Pont De Nemours And Company Macrocyclic polyamines as sensitizers for silver halide emulsions
JPS61226751A (ja) 1985-03-30 1986-10-08 Konishiroku Photo Ind Co Ltd ハロゲン化銀写真感光材料用処理液及びその処理方法
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5096724A (en) 1988-06-03 1992-03-17 Aquanautics Corporation Methods, compositions, and systems for ligand extraction
GB9001245D0 (en) 1990-01-19 1990-03-21 Salutar Inc Compounds
CA2072934C (en) 1991-07-19 2007-08-28 Karl William Aston Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
DE69224839T2 (de) 1991-07-19 1998-10-08 Monsanto Co Mangan-Komplexe mit Stickstoff enthaltenden makrozyklischen Liganden, wirksam als Superoxiddismutasekatalysatoren.
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6204259B1 (en) 1993-01-14 2001-03-20 Monsanto Company Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
CZ307096A3 (en) 1994-04-22 1997-09-17 Monsanto Co Methods of video analysis by making use of metal complexes of nitrogen-containing macrocyclic ligands
US6245758B1 (en) 1994-05-13 2001-06-12 Michael K. Stern Methods of use for peroxynitrite decomposition catalysts, pharmaceutical compositions therefor
JPH0840941A (ja) 1994-07-29 1996-02-13 Kanegafuchi Chem Ind Co Ltd 炎症性腸疾患治療製剤
US6525041B1 (en) 1995-06-06 2003-02-25 Pharmacia Corporation Manganese or iron complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide
WO1997006824A2 (en) * 1995-08-17 1997-02-27 Monsanto Company Bioconjugates of manganese complexes and their application as catalysts
EP0844889A1 (en) 1995-08-17 1998-06-03 Monsanto Company Methods of diagnostic image analysis using metal complexes of nitrogen-containing macrocyclic ligands
WO1997006830A1 (en) 1995-08-17 1997-02-27 Monsanto Company Methods of diagnostic image analysis using bioconjugates of metal complexes of nitrogen-containing macrocyclic ligands
US6180620B1 (en) * 1997-06-20 2001-01-30 G.D. Searle & Co. Analgesic methods using synthetic catalysts for the dismutation of superoxide radicals
US20020128248A1 (en) 1997-06-20 2002-09-12 Metaphore Pharmaceuticals, Inc SODm therapy for prevention and/or treatment of inflammatory disease
US20060270639A1 (en) 1997-06-20 2006-11-30 Daniela Salvemini Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20050171198A1 (en) 1997-06-20 2005-08-04 Metaphore Pharmaceuticals, Inc. SODm therapy for treatment, prevention, inhibition and reversal of inflammatory disease
US6214817B1 (en) 1997-06-20 2001-04-10 Monsanto Company Substituted pyridino pentaazamacrocyle complexes having superoxide dismutase activity
JP2991172B2 (ja) 1997-10-24 1999-12-20 日本電気株式会社 半導体装置
DE69813898T2 (de) 1997-11-03 2004-03-11 Duke University Substituierte porphyrinen
GB9817845D0 (en) 1998-08-17 1998-10-14 Glaxo Group Ltd Chemical compounds
US6040330A (en) * 1999-01-08 2000-03-21 Bionumerik Pharmaceuticals, Inc. Pharmaceutical formulations of taxanes
ES2240101T3 (es) * 1999-05-27 2005-10-16 Monsanto Company Biomateriales modificados con mimeticos de superoxido dismutasa.
US6448239B1 (en) 1999-06-03 2002-09-10 Trustees Of Princeton University Peroxynitrite decomposition catalysts and methods of use thereof
JP2003502372A (ja) 1999-06-23 2003-01-21 エリック・エフ・バーンスタイン 創傷治癒および光傷害の防止におけるニトロキシドの使用
JP5074652B2 (ja) 2000-02-08 2012-11-14 ライスユニバーシティ 治療法および診断法において使用される光学活性なナノ粒子
US7279160B2 (en) 2000-05-02 2007-10-09 The Uab Research Foundation Combinations of DR5 antibodies and other therapeutic agents
EP1315481B1 (de) 2000-08-29 2006-12-06 Mepha AG Arzneimittel zur behandlung von darmerkrankungen
US6589948B1 (en) * 2000-11-28 2003-07-08 Eukarion, Inc. Cyclic salen-metal compounds: reactive oxygen species scavengers useful as antioxidants in the treatment and prevention of diseases
US7166910B2 (en) 2000-11-28 2007-01-23 Knowles Electronics Llc Miniature silicon condenser microphone
US20020072512A1 (en) 2000-12-08 2002-06-13 Metaphore Pharmaceuticals, Inc Method of preventing and treating HIV-mediated central nervous system damage
DE60235955D1 (de) 2001-01-05 2010-05-27 Metaphore Pharmaceuticals Inc Zusammensetzungen und verfahren zur erhöhung der zytokin-aktivität und zur behandlung der hypotension assoziiert mit der verabreichung von zytokinen
DK1392328T3 (da) * 2001-01-19 2009-11-09 Nat Jewish Health Medikament til beskyttelse i radioterapi
AU2002236861A1 (en) 2001-01-26 2002-08-06 Metaphore Pharmaceuticals, Inc. Method of treatment of neurodegenerative disorders using pentaaza-macrocyclic ligand complexes
US20040137638A1 (en) 2002-03-04 2004-07-15 Slomczynska Urszula J. Chromatography of metal complexes
JP4369124B2 (ja) * 2001-03-02 2009-11-18 メタファー・ファーマシューティカルズ・インコーポレイテッド 金属錯体のクロマトグラフィー
WO2002100395A1 (en) 2001-06-08 2002-12-19 Genzyme Corporation Bismuth salts of anti-oxidants and radical scavengers for prevention and treatment of mucous membrane ulcers
US20040132706A1 (en) 2001-10-05 2004-07-08 Daniela Salvemini Composition comprising a catalyst for the dismutation of superoxide and use of the composition for preventing and treating hypotension
EP1506285B1 (en) 2001-11-01 2010-12-08 Uab Research Foundation Combinations of anti-dr5 antibodies and anti-dr4 antibodies and other therapeutic agents
DE60231246D1 (de) * 2001-12-14 2009-04-02 Alcon Inc Superoxiddismutas-mimetika zur behandlung von augenerkrankungen
JP2005530738A (ja) 2002-04-16 2005-10-13 アイシス・イノヴェイション・リミテッド 組織障害の予防及び/又は治療のためのクルクミン
US20050101581A1 (en) 2002-08-28 2005-05-12 Reading Christopher L. Therapeutic treatment methods 2
US6781231B2 (en) 2002-09-10 2004-08-24 Knowles Electronics Llc Microelectromechanical system package with environmental and interference shield
US6798047B1 (en) 2002-12-26 2004-09-28 Amkor Technology, Inc. Pre-molded leadframe
WO2005042718A2 (en) 2003-10-31 2005-05-12 Metaphore Pharmaceuticals, Inc. Compositions and methods for treating, preventing, reversing and inhibiting pain
FR2863892B1 (fr) 2003-12-18 2007-05-11 Univ Paris Descartes Utilisation de mimetiques de la superoxyde dismutase et de la glutathion reductase comme anti-cancereux
WO2005070126A2 (en) 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
AU2005231336A1 (en) 2004-03-29 2005-10-20 Inotek Pharmaceuticals Corporation Pyridyl-Substituted Porphyrin Compounds and methods of use thereof
US7262498B2 (en) 2004-10-19 2007-08-28 Hewlett-Packard Development Company, L.P. Assembly with a ring and bonding pads formed of a same material on a substrate
US20070148154A1 (en) 2004-12-17 2007-06-28 Universite Rene Descartes (Paris V) Use of superoxide dismutase mimetics and reductase gultatione in the form of anticancer drugs
US8217166B2 (en) 2005-05-05 2012-07-10 Galera Therapeutics, Llc Polyethylene glycolated superoxide dismutase mimetics
WO2006083508A2 (en) 2005-01-10 2006-08-10 Metaphore Pharmaceuticals Inc. Combinations of superoxide dismutase mimetics and nonsteroidal analgesic/anti-inflammatory drugs
US20090099150A1 (en) 2005-01-19 2009-04-16 Daniela Salvemini Methotrexate Combinations For Treating Inflammatory Diseases
AU2006230292A1 (en) 2005-03-31 2006-10-05 Schering Corporation Spirocyclic thrombin receptor antagonists
CN2870352Y (zh) 2005-12-23 2007-02-14 瑞声声学科技(深圳)有限公司 微机电系统传声器扣合式封装结构
EP2020998A4 (en) 2006-05-23 2010-07-21 Univ Utah Res Found Compositions and methods for the inhibition of endothelial nitric oxide synthase activity
US20080139525A1 (en) 2006-08-31 2008-06-12 The Brigham And Women's Hospital, Inc. Antioxidant therapies
US20080161324A1 (en) 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
LT2056675T (lt) 2006-10-12 2019-05-27 Galera Labs, Llc Burnos gleivinės mukozito gydymo būdai
TWI333264B (en) 2007-01-10 2010-11-11 Advanced Semiconductor Eng Packaging structure and method of mems microphone
JP2011505335A (ja) * 2007-09-11 2011-02-24 モンドバイオテック ラボラトリーズ アクチエンゲゼルシャフト 治療剤としてのTRP−6−トリプトレリンおよびD−Leu6−ロイプロリドの使用
CN101969926A (zh) 2008-02-29 2011-02-09 赛多仕有限公司 拓扑替康即用溶液
CA2720846A1 (en) 2008-04-15 2009-11-05 Intermune, Inc. Novel inhibitors of hepatitis c virus replication
EP2859916B1 (en) * 2008-05-22 2017-11-29 Galera Labs, LLC Combination of an antimitotic agent and a selective superoxide dismutase mimetic in antitumor therapy
WO2011113019A2 (en) 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Ctla4 proteins and their uses
US20120207687A1 (en) 2011-01-14 2012-08-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Topical formulations of targeted nitroxide agents
CA3120505C (en) 2011-09-26 2024-11-12 Galera Labs, Llc METHODS OF TREATING DISEASES
US9238659B2 (en) 2012-11-19 2016-01-19 The University Of Hong Kong Method of using binuclear gold (I) compounds for cancer treatment
UA126788C2 (uk) 2015-08-11 2023-02-08 Ґалера Лебз, Елелсі Комплексні сполуки, що містять макроциклічне кільце пентаази, які мають пероральну біодоступність
MX393974B (es) 2016-05-03 2025-03-24 Galera Labs Llc Terapia de combinacion para tratamiento de cancer.
JP7166634B2 (ja) 2016-09-01 2022-11-08 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニー ペンタアザ大環状環複合体およびアスコルビン酸化合物による組み合わせ癌療法
US20190350867A1 (en) 2016-12-27 2019-11-21 Soon Kap Hahn Prevention of local tumor recurrence following surgery using sustained and/or delayed release of medicaments contained in micro-particles
JP2020507598A (ja) 2017-02-15 2020-03-12 ガレラ・ラブス・リミテッド・ライアビリティ・カンパニーGalera Labs, Llc 局所腸送達のためのペンタアザマクロ環錯体
EP3388082A1 (en) 2017-04-13 2018-10-17 Galera Labs, LLC Combination cancer immunotherapy with pentaaza macrocyclic ring complex
MX2019012259A (es) 2017-04-13 2020-02-26 Galera Labs Llc Inmunoterapia combinada contra el cancer con complejo de anillo pentaazamacrociclico.
EA201992431A1 (ru) 2017-10-13 2020-03-13 ГАЛЕРА ЛЭБЗ, ЭлЭлСи Комбинированная иммунотерапия рака с использованием пента-аза-макроциклического кольцевого комплекса
AU2019215032A1 (en) 2018-01-31 2020-09-10 Board Of Regents Of The University Of Texas System Combination cancer therapy with pentaaza macrocyclic ring complex and platinum-based anticancer agent

Similar Documents

Publication Publication Date Title
JP2025131753A5 (enExample)
JP2018184465A5 (enExample)
JP2018035162A5 (enExample)
US20240350439A1 (en) Calcium lactate compositions and methods of use
CN106687110B (zh) 一种纯化的治疗性纳米粒子及其制备方法
JP2020183416A5 (enExample)
RU2010114042A (ru) Применение пептида в качестве терапевтического средства
CN109970987B (zh) Mof材料、纳米载药材料、药物组合物及其应用
WO2007134534A1 (fr) Solution aqueuse de composition pharmaceutique de 20(r)-ginsenoside rg3 et procédé correspondant
JP2014088444A5 (enExample)
SG193453A1 (en) Nanoparticles loaded with chemotherapeutic antitumoral drug
JP2014521658A5 (enExample)
JP2015524444A5 (enExample)
JP2020183416A (ja) 疾患の治療方法
JP2018533589A5 (enExample)
RU2010113989A (ru) Применение пептида в качестве терапевтического средства
JP2019512495A5 (enExample)
RU2017115990A (ru) Ингаляционная лекарственная форма рапамицина для лечения легочной гипертензии
JP2013542263A5 (enExample)
JP6029808B2 (ja) 併用療法における(+)−1,4−ジヒドロ−7−[(3s,4s)−3−メトキシ−4−(メチルアミノ)−1−ピロリジニル]−4−オキソ−1−(2−チアゾリル)−1,8−ナフチリジン−3−カルボン酸の使用方法
CN103370066B (zh) 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法
JP2023551046A (ja) Pik3ca変異癌の治療のための併用療法
CN109498627A (zh) 一种治疗肿瘤的药物组合物及其应用
RU2358730C2 (ru) Производное эпотилона для лечения гепатомы и других раковых заболеваний
JP2012525358A5 (enExample)